MedTrace Logo

Study Evaluating The Coadministration of Begacestat And Donepezil

NCT00959881 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2011-04-04

No results posted yet for this study

Summary

This study examines the cardiac effects (effects on the heart) of administering donepezil and begacestat together to healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

Donepezil plus placebo

5- and 10-mg tablets, single dose

DRUG

Donepezil

5- and 10-mg tablets, single dose

DRUG

Begacestat

6 x 50-mg capsules, single dose

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959881 on ClinicalTrials.gov